Eisai Clinical Trials
Study Overview
E2609
elenbecestat
NCT02956486, EU CTR 2016-004128-42
Dec 2016 - Jan 2020
Alzheimer's disease
1. Core Phase: Change From Baseline up to Month 24 in the Clinical Dementia Rating-sum of Boxes (CDR-SB) Score [ Time Frame: Baseline (Day 1: before first dose in the core phase) up to Month 24 of the core phase ]
2. Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) [ Time Frame: From first dose of study drug up to approximately 6 months (including 1 month follow up) for the extension phase ]
2. Extension Phase: Number of Participants Reporting One or More Treatment-emergent Adverse Events (TEAEs) [ Time Frame: From first dose of study drug up to approximately 6 months (including 1 month follow up) for the extension phase ]
-
Males and females (age 50 years to 85 years)
-
Terminated -
Phase 3
Bulgaria, Czechia, France, Germany, Greece, Japan, Korea, Republic of, Poland, Portugal, Russian Federation, Slovakia (Slovak Republic), Spain, United States See moreData Sharing
ClinicalStudyDataRequest.com (CSDR) is a multi sponsor site through which qualified researchers who wish to access clinical trial data and associated information in order to conduct further research can submit their research proposal or enquiry.
CSDR Sharing is not available for this study.
CSDR Availability Clinical Trial Data Redacted documents may be available upon request for this study.
Document type Availability Protocol SAP Sample CRF Full CSR